1265 related articles for article (PubMed ID: 33452206)
21. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
22. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
Bürkle A; Niedermeier M; Schmitt-Gräff A; Wierda WG; Keating MJ; Burger JA
Blood; 2007 Nov; 110(9):3316-25. PubMed ID: 17652619
[TBL] [Abstract][Full Text] [Related]
24. C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.
Zhang C; Cao K; Yang M; Wang Y; He M; Lu J; Huang Y; Zhang G; Liu H
Oncoimmunology; 2023; 12(1):2261242. PubMed ID: 37791232
[TBL] [Abstract][Full Text] [Related]
25. IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.
Pimenta EM; De S; Weiss R; Feng D; Hall K; Kilic S; Bhanot G; Ganesan S; Ran S; Barnes BJ
Immunol Cell Biol; 2015; 93(5):486-99. PubMed ID: 25533286
[TBL] [Abstract][Full Text] [Related]
26. CXCL13/CXCR5 signaling axis in cancer.
Hussain M; Adah D; Tariq M; Lu Y; Zhang J; Liu J
Life Sci; 2019 Jun; 227():175-186. PubMed ID: 31026453
[TBL] [Abstract][Full Text] [Related]
27. Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment.
Ohandjo AQ; Liu Z; Dammer EB; Dill CD; Griffen TL; Carey KM; Hinton DE; Meller R; Lillard JW
Sci Rep; 2019 Oct; 9(1):14963. PubMed ID: 31628349
[TBL] [Abstract][Full Text] [Related]
28. Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.
Hsieh CH; Jian CZ; Lin LI; Low GS; Ou PY; Hsu C; Ou DL
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053457
[TBL] [Abstract][Full Text] [Related]
29. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
[TBL] [Abstract][Full Text] [Related]
30. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
[TBL] [Abstract][Full Text] [Related]
31. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
[TBL] [Abstract][Full Text] [Related]
32. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
33. Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer.
Cao K; Zhang G; Yang M; Wang Y; He M; Zhang C; Huang Y; Lu J; Liu H
Cancer Res; 2023 Jul; 83(13):2171-2186. PubMed ID: 37172314
[TBL] [Abstract][Full Text] [Related]
34. CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma.
Lin X; Zhao X; Chen Y; Yang R; Dai Z; Li W; Lin C; Cao W
Int J Immunopathol Pharmacol; 2024; 38():3946320241227312. PubMed ID: 38252495
[No Abstract] [Full Text] [Related]
35. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.
Truxova I; Kasikova L; Hensler M; Skapa P; Laco J; Pecen L; Belicova L; Praznovec I; Halaska MJ; Brtnicky T; Salkova E; Rob L; Kodet R; Goc J; Sautes-Fridman C; Fridman WH; Ryska A; Galluzzi L; Spisek R; Fucikova J
J Immunother Cancer; 2018 Dec; 6(1):139. PubMed ID: 30526667
[TBL] [Abstract][Full Text] [Related]
36. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
[TBL] [Abstract][Full Text] [Related]
37. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
38. Interruption of CXCL13-CXCR5 axis increases upper genital tract pathology and activation of NKT cells following chlamydial genital infection.
Jiang J; Karimi O; Ouburg S; Champion CI; Khurana A; Liu G; Freed A; Pleijster J; Rozengurt N; Land JA; Surcel HM; Tiitinen A; Paavonen J; Kronenberg M; Morré SA; Kelly KA
PLoS One; 2012; 7(11):e47487. PubMed ID: 23189125
[TBL] [Abstract][Full Text] [Related]
39. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
40. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
